文献速递前列腺癌

精准引导与系统穿刺对比:优化继发性前列腺癌可疑多参数磁共振病灶的穿刺评估

Precision-guidance vs Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious Multiparametric Magnetic Resonance Imaging Lesions.
PubMed 文献 · J Urol · 2022-08-24

研究纳入571例接受靶向联合系统穿刺、且存在索引病灶与继发病灶(PI-RADS评分≥3)的患者,回顾性比较仅靶向穿刺索引+继发病灶与再加系统穿刺的临床显著前列腺癌检出率。结果显示两组检出率38% vs 42%(P=.2),但系统穿刺使中位穿刺针数从9针增至25针(P<.001)。作者认为继发病灶应纳入靶向穿刺方案,而索引+继发病灶靶向穿刺后加做系统穿刺对总体临床显著前列腺癌检出价值有限;当两病灶同侧时,推荐对侧系统穿刺以获取前列腺叶信息。

要点

  • 索引+继发病灶靶向穿刺与再加系统穿刺的临床显著前列腺癌检出率分别为38%与42%(P=.2),无显著差异。
  • 加做系统穿刺使中位穿刺针数从9针显著增至25针(P<.001)。
  • 同侧索引+继发病灶者中,对侧系统穿刺检出临床显著前列腺癌17%;其中无任何临床显著前列腺癌的亚组为3.8%。

核心结论

  • 继发病灶靶向穿刺应纳入靶向穿刺方案,因其提供额外诊断信息;但索引+继发病灶靶向穿刺后加做系统穿刺对总体临床显著前列腺癌检出价值有限。
  • 当索引与继发病灶位于同侧时,推荐对侧系统穿刺以获取前列腺叶信息。
  • 作者指出结果提示有很大潜力减少系统穿刺针数及相关潜在并发症,并需前瞻性评估。

研究设计与样本

  • 索引病灶定义为PI-RADS评分最高和/或病灶体积最大者,继发病灶为其余病灶。
  • 比较索引+继发病灶与索引+继发病灶+系统穿刺的临床显著前列腺癌(Gleason分级分组≥2)检出率。
  • 对同侧索引+继发病灶者进行亚组分析,聚焦对侧系统穿刺。
  • 多因素logistic回归预测任何临床显著前列腺癌,变量包括年龄、既往穿刺史、PSA密度、索引/继发病灶体积、侧别关系、PI-RADS分层、靶向与系统穿刺针数。

主要发现

  • 索引+继发病灶 vs 索引+继发病灶+系统穿刺的临床显著前列腺癌检出率为38% vs 42%(P=.2)。
  • 索引+继发病灶 vs 索引+继发病灶+系统穿刺的中位穿刺针数为9 vs 25(P<.001)。
  • 同侧索引+继发病灶亚组(n=236)中,对侧系统穿刺检出临床显著前列腺癌17%。
  • 同侧索引+继发病灶且无任何临床显著前列腺癌的亚组(n=131)中,对侧系统穿刺检出临床显著前列腺癌3.8%。
  • 多因素logistic回归证实对侧系统穿刺为独立预测因子,但不含系统穿刺信息时模型表现相似(AUC 87.1% vs 86.6%)。

临床怎么用

  • 作者认为继发病灶靶向穿刺应纳入靶向穿刺方案。
  • 作者认为索引+继发病灶靶向穿刺后加做系统穿刺对总体临床显著前列腺癌检出价值有限。
  • 作者建议当索引与继发病灶位于同侧时,对侧系统穿刺应被推荐用于获取前列腺叶信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the diagnostic yield of consecutive transperineal targeted biopsy of multiparametric magnetic resonance imaging index lesion and secondary lesion and additive systematic biopsy in patients who received combined targeted biopsy+systematic biopsy of prostate. MATERIALS AND METHODS: Of 1,467 patients with targeted biopsy+systematic biopsy, analyses were restricted to 571 patients with index lesion+secondary lesion, Prostate Imaging-Reporting and Data System score ≥3. Index lesion was defined as having the greatest Prostate Imaging-Reporting and Data System score and/or lesion volume as opposed to secondary lesion. We retrospectively compared clinically significant prostate cancer rates (ie, Gleason Grade Group ≥2) between index lesion+secondary lesion and index lesion+secondary lesion+systematic biopsy. Subgroup analyses in men with ipsilateral index lesion+secondary lesion focused on contralateral systematic biopsy. Multivariable logistic regression analyses to predict any clinically significant prostate cancer included age, previous biopsies, prostate specific antigen density, respective index lesion/secondary lesion volumes, side relation, Prostate Imaging-Reporting and Data System strata, and number of targeted biopsy and systematic biopsy cores. RESULTS: Clinically significant prostate cancer rates for index lesion+secondary lesion vs index lesion+secondary lesion+systematic biopsy were 38% vs 42% (P = .2) at expense of significantly higher median number of biopsy cores (9 vs 25, P < .001). In the subgroup with ipsilateral index lesion+secondary lesion (n = 236), contralateral systematic biopsy detected clinically significant prostate cancer in 17%. In the narrower subgroup with ipsilateral index lesion+secondary lesion (n = 131) without any clinically significant prostate cancer, contralateral systematic biopsy detected clinically significant prostate cancer in 3.8%. Multivariable logistic regression analyses confirmed contralateral systematic biopsy as independent predictor, but performed similarly without systematic biopsy information (area under the curve 87.1% vs 86.6%). CONCLUSIONS: Targeted biopsy of secondary lesion should be included in targeted biopsy protocols due to added diagnostic information. However, for targeted biopsy of index lesion+secondary lesion additional systematic biopsy is of limited informative value in terms of overall clinically significant prostate cancer detection. However, when index lesion+secondary lesion are ipsilateral, contralateral systematic biopsy should be recommended for purpose of prostate lobe information. Our results indicate great potential to reduce systematic biopsy cores and associated potential morbidity, and warrant prospective evaluation.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Rachubinski P, Witt JH, Budäus L, et al. Precision-guidance vs Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious Multiparametric Magnetic Resonance Imaging Lesions. J Urol. 2022. PMID: 36001731. doi:10.1097/JU.0000000000002921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。